Antibody Drug Conjugates Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drugs (Kadcyla, Adcertis), By Mechanism Of Action (CD30 Antibodies, HER2 Antibodies), By Application (Breast Cancer, Lymphoma) and Region Forecast 2019-2030  

Antibody Drug Conjugates Market size was valued at US$ 7.54 billion in 2023 and is poised to grow at a significant CAGR of 12.6% during the forecast period 2024-2030. ADCs are a type of biopharmaceutical used to treat cancer that consists of an antibody that selectively targets a tumour antigen and a cytotoxic agent linked together by a chemical linker. ADCs are designed to allow the cytotoxic substance to be targeted specifically to kill cancer cells while having a minimal effect on healthy tissue. Antibody drug conjugates are made up of three parts: an antibody specific for the target associated antigen, an antigen that has limited expression on normal cells, a cytotoxic agent that kills target cancer cells, and a chemical linker that connects the cytotoxic agent to the antibody.

Antibody drug conjugates have therapeutic potential but face technological and developmental obstacles. Antibody drug conjugates are thought to be the next generation of therapeutics. They combine the ability of monoclonal antibodies to target specific cells with the ability of cytotoxic medicines to kill those cells. Only with rising technological developments has this technology been able to succeed. Antibody drug conjugates are a new therapeutic class that is attracting the attention of both large and small pharmaceutical businesses.

Key Development

• In September 2017, Pfizer, Inc. received FDA approval for the Mylotarg (Gemtuzumab Ozogamicin), and antibody drug conjugate used in newly diagnosed and relapsed or refractory CD33-Positive acute myeloid leukemia.